{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7267.6","upperLimit":"11168.1","value":"9217.85"},{"groupId":"OG001","lowerLimit":"3993.55","upperLimit":"5139","value":"4492.92"},{"groupId":"OG002","lowerLimit":"4629.88","upperLimit":"5747.95","value":"5383.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Steady State AUC for lorlatinib in patients in cohort A2","dispersionType":"Full Range","groups":[{"description":"Lorlatinib will be given at 100 mg orally once daily continuously for 28 days. Patients must be 18 years of age or older at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG000","title":"Cohort A2 DL 3A"},{"description":"Lorlatinib will be given at 150 mg orally once daily continuously for 28 days. Patients must be 18 years of age or older at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG001","title":"Cohort A2 DL4A"},{"description":"Lorlatinib will be given at 150 mg orally once daily continuously for 28 days. Patients must be 18 years of age or older at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG002","title":"Cohort A2 DL4A Expansion"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 15 (0, 1, 2, 24, 360, 361, 362, 364, 366 hours post-initial dose)","title":"Pharmacokinetics A2-Steady State AUC","type":"SECONDARY","unitOfMeasure":"hours*ng/mL"}